Zymergen IPO
Zymergen was a synthetic biology company that used machine learning and automation to engineer microbes for manufacturing chemicals, materials, and other products. The company attracted significant investor interest as a leader in the emerging field of biomanufacturing before being acquired by Ginkgo Bioworks.
Key Facts
| Industry | Synthetic Biology and Biomanufacturing |
| Founded | 2013 |
| Headquarters | Emeryville, CA |
| Employees | Acquired (previously ~900) |
| Website | zymergen.com |
| Funding | Acquired by Ginkgo Bioworks for $300M in 2022. Previously raised ~$400M |
About Zymergen
Zymergen pioneered the application of machine learning and automation to synthetic biology, developing a platform that could engineer microorganisms to produce specialty chemicals, materials, and pharmaceuticals at industrial scale. The company's approach combined robotics, artificial intelligence, and genetic engineering to accelerate the traditionally slow process of developing biological manufacturing processes. Zymergen's platform could test thousands of genetic variants simultaneously, dramatically reducing the time needed to optimize microbial production.
Despite raising over $400 million and going public in 2021, Zymergen struggled to commercialize its technology platform effectively and was acquired by Ginkgo Bioworks for $300 million in late 2022, significantly below its previous valuation. The acquisition represented a consolidation in the synthetic biology space, with Ginkgo absorbing Zymergen's automation capabilities and talent. Zymergen's challenges highlighted the difficulties in translating advanced biotechnology platforms into profitable commercial products, even with sophisticated technology and substantial funding.
IPO Status
Zymergen was acquired by Ginkgo Bioworks in September 2022 for approximately $300 million in cash and stock. The acquisition came after Zymergen had raised substantial venture funding, including a $300 million Series C round in 2018 that valued the company at $3.2 billion. Prior to the acquisition, Zymergen had been considered a potential IPO candidate given its high valuation and position in the growing synthetic biology market. However, the company faced challenges scaling its business model and achieving profitability, ultimately leading to the strategic sale to Ginkgo Bioworks, which sought to integrate Zymergen's automation and strain engineering capabilities.
Competitors
Frequently Asked Questions
Does Zymergen have a stock?
No, Zymergen never had an IPO. The company was acquired by Ginkgo Bioworks in 2022 before going public.
When is the Zymergen IPO date?
There is no Zymergen IPO date as the company was acquired by Ginkgo Bioworks in September 2022. Zymergen will not have an IPO since it is now part of Ginkgo Bioworks.
How can I buy Zymergen stock?
You cannot buy Zymergen stock directly as it was acquired by Ginkgo Bioworks in 2022. If you're interested in exposure to Zymergen's technology, you could consider investing in Ginkgo Bioworks, which trades under the ticker DNA.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts